NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy - Hurtado-Navarro L; Cuenca-Zamora EJ; Zamora L; Bellosillo B; Such E; Soler-Espejo E; Martínez-Banaclocha H; Hernández-Rivas JM; Marco-Ayala J; Martínez-Alarcón L; Linares-Latorre L; García-Ávila S; et al. (Cell Reports Medicine, 2023)